Stay updated on ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial
Sign up to get notified when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.

Latest updates to the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check77 days agoChange DetectedThe web page has undergone significant updates, including the removal of detailed study protocols and inclusion criteria for a clinical trial on enfortumab vedotin, while adding new collaborators and a revision number.SummaryDifference36%
- Check84 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.